Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group

• Published in: The New England journal of medicine Vol. 327; no. 3; pp. 163 - 167
• Main Authors: Caldwell-Brown, D, Stern, R S, Lin, A N, Carter, D M
• Format: Journal Article
• Language: English
• Published: United States 16.07.1992
• Subjects: Adolescent; Child; Double-Blind Method; Drug Administration Schedule; Epidermolysis Bullosa Dystrophica - drug therapy; Epidermolysis Bullosa Dystrophica - pathology; Female; Humans; Male; Phenytoin - administration & dosage; Phenytoin - therapeutic use; Skin - pathology
• ISSN: 0028-4793

Recessive dystrophic epidermolysis bullosa is an uncommon, severely disabling, heritable disorder characterized by abnormal fragility of the skin. Open trials have suggested that phenytoin is an effective treatment, and this therapy is now widely used. To determine the efficacy of phenytoin in the treatment of recessive dystrophic epidermolysis bullosa, we performed a randomized, double-blind, placebo-controlled, crossover trial in 36 patients. Each treatment was given for five to seven months, separated by a two-month period. We measured the total number of blisters and erosions on the entire body, the size of three plaques containing blisters and erosions, and the number of blisters and erosions in the three plaques at the beginning and end of each treatment period in each patient. Twenty-two patients completed both courses of therapy, seven patients completed one course, and seven patients withdrew before completing a single course. There was no significant difference in disease activity between phenytoin treatment and placebo treatment, as measured by changes in the number of blisters and erosions on the entire body (7 percent decrease vs. 6 percent increase), in the area of three designated plaques (0.4 percent decrease vs. 0.2 percent increase), or in the number of blisters and erosions in the designated plaques (12 percent decrease vs. 31 percent increase). Phenytoin is not an effective treatment for patients with recessive dystrophic epidermolysis bullosa.